Open Access Open Access  Restricted Access Subscription Access

An Essential Parameters of Tobramycin Include Indications, Mechanism of Action, Adverse Effects and Toxicity

Dr. Guduru Rajeswari, Dr. P. Prabhavathi, Pothuraju Ramudu, Vonteru Munisekhar, K. Suparnalatha, M. Harshita, A. Vidyadhari, Talamanchi Geethika

Abstract


Tobramycin is a useful antibiotic that is frequently used to treat and manage a variety of ocular and systemic infections. Tobramycin is an aminoglycoside antibiotic that works against Pseudomonas aeruginosa and other aerobic gram-negative bacteria. Tobramycin is used to treat both superficial and deep infections due to its wide range of action. In order to support the healthcare team in making decisions and providing the best possible patient care, this activity describes a thorough review of the indications, mechanisms of action, potential toxicities, off label uses, dosing considerations, pharmacodynamics, pharmacokinetics, monitoring requirements, and pertinent drug interactions related to tobramycin.


Full Text:

PDF

References


Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016). Aminoglycosides: An overview. Cold Spring Harbor Perspectives in Medicine, 6(6).

Kotra, L. P., Haddad, J., & Mobashery, S. (2000). Aminoglycosides: Perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrobial Agents and Chemotherapy, 44(12), 3249–3256.

Periti, P. (1996). Tobramycin—clinical pharmacology and chemotherapy. Journal of Chemotherapy, 8(Suppl. 1), 3–30.

Mingeot-Leclercq, M. P., Glupczynski, Y., & Tulkens, P. M. (1999). Aminoglycosides: Activity and resistance. Antimicrobial Agents and Chemotherapy, 43(4), 727–737.

Wilhelmus, K. R., Gilbert, M. L., & Osato, M. S. (1987). Tobramycin in ophthalmology. Survey of Ophthalmology, 32(2), 111–122.

Hagerman, J. K., Knechtel, S. A., & Klepser, M. E. (2007). Tobramycin solution for inhalation in cystic fibrosis patients: A review of the literature. Expert Opinion on Pharmacotherapy, 8(4), 467–475.

Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Mueller, G., Hadjiliadis, D., Hoag, J. B., Lubsch, L., Hazle, L., Sabadosa, K., & Marshall, B. (2013). Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine, 187(7), 680–689.

Tunkel, A. R., Hasbun, R., Bhimraj, A., Byers, K., Kaplan, S. L., Scheld, W. M., van de Beek, D., Bleck, T. P., Garton, H. J. L., & Zunt, J. R. (2017). 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clinical Infectious Diseases, 64(6), e34–e65.

Bonilla, F. A., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Hsu, J. T., Keller, M., Kobrynski, L. J., Komarow, H. D., Mazer, B., Nelson, R. P., Orange, J. S., Routes, J. M., Shearer, W. T., Sorensen, R. U., Verbsky, J. W., Bernstein, D. I., Blessing-Moore, J., Lang, D., . . . Wallace, D. (2015). Practice parameter for the diagnosis and management of primary immunodeficiency. Journal of Allergy and Clinical Immunology, 136(5), 1186–1205.e1–e78.

Davis, B. D. (1987). Mechanism of bactericidal action of aminoglycosides. Microbiological Reviews, 51(3), 341–350.

Davis, B. D., Chen, L. L., & Tai, P. C. (1986). Misread protein creates membrane channels: An essential step in the bactericidal action of aminoglycosides. Proceedings of the National Academy of Sciences of the United States of America, 83(16), 6164–6168.

Israel, K. S., Welles, J. S., & Black, H. R. (1976). Aspects of the pharmacology and toxicology of tobramycin in animals and humans. The Journal of Infectious Diseases, 134(Suppl.), S97–S103.

Rosenfeld, M., Gibson, R., McNamara, S., Emerson, J., McCoyd, K. S., Shell, R., Borowitz, D., Konstan, M. W., Retsch-Bogart, G., Wilmott, R. W., Burns, J. L., Vicini, P., Montgomery, A. B., & Ramsey, B. (2001). Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. The Journal of Pediatrics, 139(4), 572–577.

Hennig, S., Standing, J. F., Staatz, C. E., & Thomson, A. H. (2013). Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clinical Pharmacokinetics, 52(4), 289–301.

Banerjee, S. K., Jagannath, C., Hunter, R. L., & Dasgupta, A. (2000). Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sciences, 67(16), 2011–2016.

National Institute of Diabetes and Digestive and Kidney Diseases. (2019, April 12). Tobramycin. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health.

Kernt, K., Martinez, M. A., Bertin, D., Stroman, D., Cupp, G., Martínez, C., Tirado, M., & Guasch, J. (2005). A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis. European Journal of Ophthalmology, 15(5), 541–549.

Wu, A. Y., Gervasio, K. A., Gergoudis, K. N., Wei, C., Oestreicher, J. H., & Harvey, J. T. (2018). Conservative therapy for chalazia: Is it really effective? Acta Ophthalmologica, 96(4), e503–e509.

Aminimanizani, A., Beringer, P. M., Kang, J., Tsang, L., Jelliffe, R. W., & Shapiro, B. J. (2002). Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 50(4), 553–559.

Tunkel, A. R., Hartman, B. J., Kaplan, S. L., Kaufman, B. A., Roos, K. L., Scheld, W. M., & Whitley, R. J. (2004). Practice guidelines for the management of bacterial meningitis. Clinical Infectious Diseases, 39(9), 1267–1284.


Refbacks

  • There are currently no refbacks.